It is still early days but Almirall SA's atopic dermatitis drug Ebglyss has made a promising start, and the Spanish firm has also been trumpeting its psoriasis drug Ilumetri after posting a healthy set of financials for the first half of 2024.
Ebglyss (lebrikizumab), which obtained EU and UK approval at the end of 2023 for moderate-to-severe atopic dermatitis and was launched in Germany in December, had sales of €10.8m in the first half, including €7.2m in the second quarter. Almirall CEO Carlos Gallardo told analysts on a 22 July call that the Eli Lilly and Company-partnered interleukin-13 inhibitor had secured a double-digit share of the new dynamic market, ie first time users and switchers, and had already passed all other approved "advanced systemics" for atopic dermatitis - LEO Pharma A/S’s anti-IL-13 Adtralza/Adbry (tralokinumab) and three JAK inhibitors, namely AbbVie Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?